FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2587731384> ?p ?o ?g. }

• W2587731384 endingPage "262" @default.
• W2587731384 startingPage "254" @default.
• W2587731384 abstract "The combination of bendamustine, bortezomib and dexamethasone (BBD) was evaluated as a first-line therapy for multiple myeloma. The original treatment regimen of bendamustine 80 mg/m2 , days 1, 4; bortezomib 1·3 mg/m2 , days 1, 4, 8, 11; dexamethasone 40 mg, days 1, 2, 3, 4 on a 28-day cycle (up to 8 cycles) was efficacious but determined relatively toxic in an interim analysis. The regimen was amended to bendamustine 80 mg/m2 , days 1, 2; bortezomib 1·3 mg/m2 , days 1, 8, 15; dexamethasone 20 mg, days 1, 2, 8, 9, 15, 16 every 28 days (up to 8 cycles), then maintenance 1·3 mg/m2 IV bortezomib every 2 weeks. Fifty-nine patients were enrolled. Primary endpoint was complete response (CR) rate. The original schema was given for a median of 7 cycles (range 1-8); modified schema was given for a median of 8 cycles (range 1-8) plus maintenance. Overall response was 91%, CR was 9%. Median follow-up was 19·1 months; median progression-free survival was 11·1 months and 18·9 months on the original and modified regimens, respectively. The most common Grade 3/4 adverse events were fatigue and neuropathy. The combination of BBD is tolerable and efficacious in this patient population. Modifications to decrease intensity but increase duration translated to better outcomes." @default.
• W2587731384 created "2017-02-17" @default.
• W2587731384 creator A5004557221 @default.
• W2587731384 creator A5008174546 @default.
• W2587731384 creator A5011559739 @default.
• W2587731384 creator A5027550311 @default.
• W2587731384 creator A5037195922 @default.
• W2587731384 creator A5044422916 @default.
• W2587731384 creator A5050961257 @default.
• W2587731384 creator A5051465004 @default.
• W2587731384 creator A5063636021 @default.
• W2587731384 date "2017-02-07" @default.
• W2587731384 modified "2023-10-14" @default.
• W2587731384 title "Phase <scp>II</scp> study of bendamustine, bortezomib and dexamethasone (<scp>BBD</scp>) in the first‐line treatment of patients with multiple myeloma who are not candidates for high dose chemotherapy" @default.
• W2587731384 cites W1846311518 @default.
• W2587731384 cites W1971650766 @default.
• W2587731384 cites W1978449163 @default.
• W2587731384 cites W2018530818 @default.
• W2587731384 cites W2037050131 @default.
• W2587731384 cites W2044436186 @default.
• W2587731384 cites W2048483323 @default.
• W2587731384 cites W2048579461 @default.
• W2587731384 cites W2074533771 @default.
• W2587731384 cites W2095255742 @default.
• W2587731384 cites W2096207943 @default.
• W2587731384 cites W2117510998 @default.
• W2587731384 cites W2128192762 @default.
• W2587731384 cites W2141105112 @default.
• W2587731384 cites W2170552969 @default.
• W2587731384 cites W2239467190 @default.
• W2587731384 cites W228849395 @default.
• W2587731384 cites W2471307268 @default.
• W2587731384 cites W2563955350 @default.
• W2587731384 cites W2593757693 @default.
• W2587731384 cites W4252175385 @default.
• W2587731384 doi "https://doi.org/10.1111/bjh.14536" @default.
• W2587731384 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/28169430" @default.
• W2587731384 hasPublicationYear "2017" @default.
• W2587731384 type Work @default.
• W2587731384 sameAs 2587731384 @default.
• W2587731384 citedByCount "4" @default.
• W2587731384 countsByYear W25877313842020 @default.
• W2587731384 countsByYear W25877313842021 @default.
• W2587731384 countsByYear W25877313842023 @default.
• W2587731384 crossrefType "journal-article" @default.
• W2587731384 hasAuthorship W2587731384A5004557221 @default.
• W2587731384 hasAuthorship W2587731384A5008174546 @default.
• W2587731384 hasAuthorship W2587731384A5011559739 @default.
• W2587731384 hasAuthorship W2587731384A5027550311 @default.
• W2587731384 hasAuthorship W2587731384A5037195922 @default.
• W2587731384 hasAuthorship W2587731384A5044422916 @default.
• W2587731384 hasAuthorship W2587731384A5050961257 @default.
• W2587731384 hasAuthorship W2587731384A5051465004 @default.
• W2587731384 hasAuthorship W2587731384A5063636021 @default.
• W2587731384 hasBestOaLocation W25877313841 @default.
• W2587731384 hasConcept C126322002 @default.
• W2587731384 hasConcept C141071460 @default.
• W2587731384 hasConcept C197934379 @default.
• W2587731384 hasConcept C2776364478 @default.
• W2587731384 hasConcept C2776694085 @default.
• W2587731384 hasConcept C2777063308 @default.
• W2587731384 hasConcept C2777478702 @default.
• W2587731384 hasConcept C2779338263 @default.
• W2587731384 hasConcept C2780401358 @default.
• W2587731384 hasConcept C2780653079 @default.
• W2587731384 hasConcept C2781413609 @default.
• W2587731384 hasConcept C2781442060 @default.
• W2587731384 hasConcept C71924100 @default.
• W2587731384 hasConcept C90924648 @default.
• W2587731384 hasConceptScore W2587731384C126322002 @default.
• W2587731384 hasConceptScore W2587731384C141071460 @default.
• W2587731384 hasConceptScore W2587731384C197934379 @default.
• W2587731384 hasConceptScore W2587731384C2776364478 @default.
• W2587731384 hasConceptScore W2587731384C2776694085 @default.
• W2587731384 hasConceptScore W2587731384C2777063308 @default.
• W2587731384 hasConceptScore W2587731384C2777478702 @default.
• W2587731384 hasConceptScore W2587731384C2779338263 @default.
• W2587731384 hasConceptScore W2587731384C2780401358 @default.
• W2587731384 hasConceptScore W2587731384C2780653079 @default.
• W2587731384 hasConceptScore W2587731384C2781413609 @default.
• W2587731384 hasConceptScore W2587731384C2781442060 @default.
• W2587731384 hasConceptScore W2587731384C71924100 @default.
• W2587731384 hasConceptScore W2587731384C90924648 @default.
• W2587731384 hasFunder F4320308970 @default.
• W2587731384 hasFunder F4320310465 @default.
• W2587731384 hasIssue "2" @default.
• W2587731384 hasLocation W25877313841 @default.
• W2587731384 hasLocation W25877313842 @default.
• W2587731384 hasOpenAccess W2587731384 @default.
• W2587731384 hasPrimaryLocation W25877313841 @default.
• W2587731384 hasRelatedWork W1991948976 @default.
• W2587731384 hasRelatedWork W2027348595 @default.
• W2587731384 hasRelatedWork W2063424779 @default.
• W2587731384 hasRelatedWork W2104706142 @default.
• W2587731384 hasRelatedWork W2104965094 @default.
• W2587731384 hasRelatedWork W2124503326 @default.
• W2587731384 hasRelatedWork W2377458274 @default.
• W2587731384 hasRelatedWork W2409439928 @default.

• next